Handelsbanken Fonder AB Lowers Stake in Medtronic PLC $MDT

Posted by George Bondi on Aug 12th, 2026

Handelsbanken Fonder AB lessened its position in Medtronic PLC (NYSE:MDT – Free Report) by 1.1% in the second quarter, HoldingsChannel.com reports. The institutional investor owned 596,254 shares of the medical technology company’s stock after selling 6,509 shares during the period. Handelsbanken Fonder AB’s holdings in Medtronic were worth $46,645,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. Vanguard Group Inc. grew its stake in Medtronic by 1.5% in the 4th quarter. Vanguard Group Inc. now owns 128,961,343 shares of the medical technology company’s stock worth $12,388,027,000 after acquiring an additional 1,888,381 shares during the period. State Street Corp raised its holdings in Medtronic by 2.0% in the 4th quarter. State Street Corp now owns 61,660,158 shares of the medical technology company’s stock valued at $5,966,780,000 after acquiring an additional 1,199,621 shares during the last quarter. JPMorgan Chase & Co. lifted its stake in shares of Medtronic by 2.7% during the 4th quarter. JPMorgan Chase & Co. now owns 53,616,694 shares of the medical technology company’s stock worth $5,150,420,000 after purchasing an additional 1,419,730 shares during the period. Capital Research Global Investors lifted its stake in shares of Medtronic by 12.6% during the 4th quarter. Capital Research Global Investors now owns 34,573,163 shares of the medical technology company’s stock worth $3,321,101,000 after purchasing an additional 3,880,174 shares during the period. Finally, Geode Capital Management LLC boosted its holdings in shares of Medtronic by 0.8% during the fourth quarter. Geode Capital Management LLC now owns 27,879,481 shares of the medical technology company’s stock worth $2,665,832,000 after purchasing an additional 231,919 shares during the last quarter. Hedge funds and other institutional investors own 82.06% of the company’s stock.

Insider Activity at Medtronic

In other news, EVP Harry Skip Kiil sold 4,189 shares of the firm’s stock in a transaction dated Monday, June 8th. The stock was sold at an average price of $80.44, for a total value of $336,963.16. Following the transaction, the executive vice president directly owned 37,227 shares in the company, valued at $2,994,539.88. This trade represents a 10.11% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.26% of the stock is currently owned by company insiders.

Key Headlines Impacting Medtronic

Here are the key news stories impacting Medtronic this week:

Positive Sentiment: Analyst upgrades reinforce the turnaround thesis. UBS upgraded Medtronic to Buy from Neutral, citing evidence that a turnaround is underway. Additional analyst upgrades point to the company’s strongest annual revenue growth in roughly a decade, driven by its cardiac portfolio and new product launches. Medtronic Wins Analyst Upgrades, Is It Fully Priced?
Positive Sentiment: Options activity signals increased bullish interest. Investors purchased 19,654 MDT call options, 56% above typical daily call volume. While this is speculative rather than a fundamental measure, it suggests rising short-term trader interest.
Positive Sentiment: Growth opportunities remain substantial in cardiac care. A new industry report projects the global pulsed-field ablation market to grow from approximately $3.2 billion in 2026 to $14.6 billion by 2035. Medtronic is listed among the major competitors that could benefit from expanding adoption of the technology. Pulsed Field Ablation Global Market Report 2026
Positive Sentiment: Pipeline collaboration is progressing. Orchestra BioMed said its BACKBEAT pivotal trial, conducted with Medtronic, remains on track to reach its enrollment target by the end of the third quarter, with primary data expected in the second quarter of 2027. Successful results could create an additional future growth driver. Orchestra BioMed Reports Second Quarter Results
Neutral Sentiment: Valuation is becoming a key investor question. After its recent advance, investors are assessing whether Medtronic’s improving outlook is already reflected in the share price. The company’s forward growth, dividend support and FY2027 EPS guidance of $5.90–$6.00 provide fundamental support, but continued gains may require evidence that the recovery is sustainable.

Medtronic Stock Up 1.3%

Shares of NYSE MDT opened at $90.55 on Wednesday. The stock has a market capitalization of $115.91 billion, a PE ratio of 24.28, a P/E/G ratio of 2.40 and a beta of 0.55. The company has a quick ratio of 1.62, a current ratio of 2.13 and a debt-to-equity ratio of 0.52. The firm has a fifty day moving average of $82.59 and a 200-day moving average of $86.48. Medtronic PLC has a 52-week low of $73.31 and a 52-week high of $106.33.

Medtronic (NYSE:MDT – Get Free Report) last issued its earnings results on Wednesday, June 3rd. The medical technology company reported $1.55 earnings per share for the quarter, topping the consensus estimate of $1.54 by $0.01. Medtronic had a return on equity of 14.51% and a net margin of 13.20%.The business had revenue of $9.81 billion for the quarter, compared to analyst estimates of $9.62 billion. During the same period last year, the company posted $1.62 EPS. The business’s quarterly revenue was up 9.9% on a year-over-year basis. Medtronic has set its FY 2027 guidance at 5.900-6.000 EPS. On average, analysts anticipate that Medtronic PLC will post 5.94 EPS for the current year.

Medtronic Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, July 17th. Shareholders of record on Friday, June 26th were paid a dividend of $0.72 per share. This is a boost from Medtronic’s previous quarterly dividend of $0.71. This represents a $2.88 annualized dividend and a yield of 3.2%. The ex-dividend date was Friday, June 26th. Medtronic’s payout ratio is currently 77.21%.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on MDT. TD Cowen lowered their price objective on Medtronic from $119.00 to $100.00 and set a “buy” rating for the company in a research report on Friday, July 10th. Wells Fargo & Company reduced their target price on Medtronic from $114.00 to $102.00 and set an “overweight” rating on the stock in a research report on Thursday, June 4th. Sanford C. Bernstein decreased their price target on Medtronic from $112.00 to $97.00 and set an “outperform” rating on the stock in a research note on Thursday, June 4th. JPMorgan Chase & Co. lowered their price target on Medtronic from $100.00 to $86.00 and set a “neutral” rating for the company in a report on Thursday, June 4th. Finally, Leerink Partners dropped their price objective on shares of Medtronic from $117.00 to $104.00 and set an “outperform” rating for the company in a research note on Thursday, June 4th. Eighteen analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $98.83.

Read Our Latest Stock Report on MDT

Medtronic Company Profile

(Free Report)

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).